[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice

Mette Munk Jensen; Kamille Dumong Erichsen; Camilla Bardram Johnbeck; Fredrik Björkling; Jacob Madsen; Peter Buhl Jensen; Maxwell Sehested; Liselotte Højgaard; Andreas Kjær

doi:10.1186/1471-2407-13-168

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice

Mette Munk Jensen
, Kamille Dumong Erichsen
, Camilla Bardram Johnbeck
, Fredrik Björkling
, Jacob Madsen
, Peter Buhl Jensen
, Maxwell Sehested
, Liselotte Højgaard
, Andreas Kjær

Department of Clinical Physiology and Nuclear Medicine

24 Citations (Scopus)

Abstract

Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[(18)F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) following treatment with belinostat in ovarian cancer in vivo models.

Original language	English
Journal	B M C Cancer
Volume	13
Pages (from-to)	168
ISSN	1471-2407
DOIs	https://doi.org/10.1186/1471-2407-13-168
Publication status	Published - 2013

Keywords

Animals
Antineoplastic Agents
Dideoxynucleosides
Disease Models, Animal
Female
Fluorodeoxyglucose F18
Glucose Transporter Type 1
Humans
Hydroxamic Acids
Ki-67 Antigen
Mice
Ovarian Neoplasms
Positron-Emission Tomography
Radiopharmaceuticals
Sulfonamides
Thymidine Kinase
Tumor Burden

Access to Document

10.1186/1471-2407-13-168

Cite this

@article{cc86d1ce36204564ada85f0380e829be,

title = "[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice",

abstract = "Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[(18)F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) following treatment with belinostat in ovarian cancer in vivo models.",

keywords = "Animals, Antineoplastic Agents, Dideoxynucleosides, Disease Models, Animal, Female, Fluorodeoxyglucose F18, Glucose Transporter Type 1, Humans, Hydroxamic Acids, Ki-67 Antigen, Mice, Ovarian Neoplasms, Positron-Emission Tomography, Radiopharmaceuticals, Sulfonamides, Thymidine Kinase, Tumor Burden",

author = "Jensen, \{Mette Munk\} and Erichsen, \{Kamille Dumong\} and Johnbeck, \{Camilla Bardram\} and Fredrik Bj{\"o}rkling and Jacob Madsen and Jensen, \{Peter Buhl\} and Maxwell Sehested and Liselotte H{\o}jgaard and Andreas Kj{\ae}r",

year = "2013",

doi = "10.1186/1471-2407-13-168",

language = "English",

volume = "13",

pages = "168",

journal = "B M C Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd",

}

TY - JOUR

T1 - [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice

AU - Jensen, Mette Munk

AU - Erichsen, Kamille Dumong

AU - Johnbeck, Camilla Bardram

AU - Björkling, Fredrik

AU - Madsen, Jacob

AU - Jensen, Peter Buhl

AU - Sehested, Maxwell

AU - Højgaard, Liselotte

AU - Kjær, Andreas

PY - 2013

Y1 - 2013

N2 - Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[(18)F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) following treatment with belinostat in ovarian cancer in vivo models.

AB - Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[(18)F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) following treatment with belinostat in ovarian cancer in vivo models.

KW - Animals

KW - Antineoplastic Agents

KW - Dideoxynucleosides

KW - Disease Models, Animal

KW - Female

KW - Fluorodeoxyglucose F18

KW - Glucose Transporter Type 1

KW - Humans

KW - Hydroxamic Acids

KW - Ki-67 Antigen

KW - Mice

KW - Ovarian Neoplasms

KW - Positron-Emission Tomography

KW - Radiopharmaceuticals

KW - Sulfonamides

KW - Thymidine Kinase

KW - Tumor Burden

U2 - 10.1186/1471-2407-13-168

DO - 10.1186/1471-2407-13-168

M3 - Journal article

C2 - 23548101

SN - 1471-2407

VL - 13

SP - 168

JO - B M C Cancer

JF - B M C Cancer

ER -

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice

Abstract

Keywords

Access to Document

Fingerprint

Cite this